WXWeilv Xu

Weilv Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weilv Xu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Fushan Shi

    Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, China

    3 shared publications
  • Yang Yang

    Key Laboratory of Applied Technology On Green-Eco-Healthy Animal Husbandry of Zhejiang Province, Zhejiang Provincial Engineering Research Center for Animal Health Diagnostics & Advanced Technology, Zhejiang International Science and Technology Cooperation Base for Veterinary Medicine and Health Management, China-Australia Joint Laboratory for Animal Health Big Data Analytics, College of Animal Science and Technology & College of Veterinary Medicine of Zhejiang A&F University, Hangzhou, China

    3 shared publications
  • Jianan Wu

    Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, China

    2 shared publications
  • Jinsong Gao

    Department of Critical Care Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Jinxin Meng

    Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, China

    2 shared publications
  • Shiyang Liu

    Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou, China

    2 shared publications

Latest Publications

  • Open Access

    The gasdermin family: from pyroptosis mechanisms to therapeutic targets

    by Weilv Xu, Shiyang Liu, Zexu Yu, Jinhuang Shi, Yang Yang, Fushan Shi

    The gasdermin (GSDM) family of proteins has emerged as the central executioner of pyroptosis, a form of inflammatory cell death characterized by plasma membrane rupture and the release of pro-inflammatory cytokines such as interleukin-1β (IL-1β), IL-18 and high mobility group protein B1 (HMGB1). Emerging evidence indicates that GSDMs exert diverse functions in health and various disease contexts, which can be either dependent on or independent of pyroptosis, including facilitating mucus secretion, regulating bone resorption, and modulating mitochondrial metabolism. This review provides a comprehensive overview of the GSDM family, detailing the molecular mechanisms of activation, regulation, pore formation, cell rupture and membrane repair. We explored the extensive crosstalk between GSDMs and other cell death modalities, including apoptosis, necroptosis, NETosis, and PANoptosis. Furthermore, we systematically discuss GSDMs’ ‘double-edged sword’ roles in diverse pathologies, ranging from host defense in infectious diseases and chronic inflammation in autoimmune disorders to their complex, context-dependent function in cancer progression and immunity. Finally, we evaluate emerging therapeutic strategies, encompassing small-molecule inhibitors such as disulfiram (DSF), necrosulfonamide (NSA) and dimethyl fumarate (DMF), as well as novel material-based delivery systems. Collectively, these advances underscore the therapeutic potential of targeting GSDMs for precise clinical intervention to treat both inflammatory and non-inflammatory diseases, as well as to enhance cancer immunotherapy.

  • Top Cited Papers
    Open Access

    A microbiota-IPA axis facilitates intestinal stem cell-mediated regeneration in colitis through a Hopx-associated program

    by Yanan Zhang, Jinxin Meng, Shuyu Tu, Linlin Ma, Xinya Zhao, Jinsong Gao, Jianan Wu, Weilv Xu, Shuxian Chen, Hairong Cheng, et al.

    The gut microbiota plays a crucial role in maintaining intestinal stem cell (ISC) homeostasis and epithelial barrier integrity. Here, we report that Blautia coccoides (B. coccoides) is significantly reduced in inflammatory bowel disease (IBD) patients and dextran sulfate sodium (DSS)-induced colitis mice. Through an integrated approach combining RNA sequencing, metabolomic profiling, and ISC lineage tracing across multiple mucosal injury models, we demonstrate that B. coccoides colonization enhances β-hydroxybutyrate (BHB) production in intestinal epithelial cells (IECs), which activates HOPX⁺ reserve ISCs and promotes regeneration of the LGR5⁺ ISC pool, thereby accelerating epithelial repair. We further show that B. coccoides-derived indole-3-lactic acid (ILA), a tryptophan (Trp) metabolite, is converted into indole-3-propionic acid (IPA) by commensal bacteria such as P. russellii or C. sporogenes, stimulating IEC BHB synthesis. Using an engineered Escherichia coli strain expressing BC-derived phenyllactate dehydrogenase (fldH), we establish that both dietary Trp and bacterial fldH activity are essential for ILA/IPA generation and subsequent mucosal healing. Our findings reveal a microbiota-metabolite-ISC regulatory axis critical for epithelial regeneration and propose novel metabolite-based therapeutic strategies for IBD and other intestinal disorders associated with barrier dysfunction.


  • Top Cited Papers
    Open Access

    Microbiota-derived IPA protects against colitis by regulating intestinal HMGCS2-mediated ketogenesis to facilitate mucosal healing

    by Yanan Zhang, Shuyu Tu, Xian Shao, Jinxin Meng, Zhuobiao Zhang, Wei Wei, Xuping Jing, Zhewen Qin, Jianan Wu, Weilv Xu, et al.

    The gut microbiota sustains intestinal homeostasis, yet how microbial metabolites direct epithelial repair remains unclear. Here we identify indole-3-propionic acid (IPA), a tryptophan-derived bacterial metabolite, as a key regulator of mucosal healing. IPA activates PPARα in intestinal epithelial cells, enhancing transcription of the ketogenic enzyme HMGCS2 and boosting β‑hydroxybutyrate (BHB) production. BHB in turn stimulates LGR5⁺ intestinal stem cells, accelerating epithelial regeneration. Using germ-free models and the IPA‑producer Peptostreptococcus russellii, we show that dietary tryptophan and specific commensals sustain luminal IPA levels, which are critical for recovery in colitis. Restoration of IPA or BHB attenuates inflammation and barrier defects, outlining a microbiota‑metabolite‑stem cell axis that could be therapeutically targeted in inflammatory bowel disease and other barrier disorders.


  • Open Access

    The Neglected Role of GSDMD C‐Terminal in Counteracting Type I Interferon Signaling

    by Weilv Xu, Suhui He, Wen Shi, Jinxia Xu, Shiyang Liu, Zexu Yu, Danyue Li, Qiao Jin, Yumeng Wang, Zian Zhang, et al.

    The GSDMD N‐terminal fragment (GSDMD‐NT)‐mediated pyroptosis is extensively investigated. However, the role of the C‐terminal domain of GSDMD (GSDMD‐CT) is unexplored. This study demonstrates that GSDMD‐CT acts as a negative regulator that suppresses IFN‐I signaling during viral infection. Mechanistically, GSDMD‐CT, released upon virus infection, interacts separately with retinoic acid‐inducible gene I (RIG‐I) and tank‐binding kinase (TBK1), promoting the selective autophagic degradation of RIG‐I via K48‐linked polyubiquitination at Lys181 and TBK1 via K27‐linked polyubiquitination at Lys487 by the E3 ligase TRIM28, which serves as a recognition signal for the cargo receptor NDP52 and TOLLIP, respectively. Moreover, the P414, Q416, and E459 amino sites are crucial for GSDMD‐CT in counteracting antiviral responses. The findings highlight the role of GSDMD‐CT in inhibiting antiviral immunity, providing insights into how viruses manipulate host defense mechanisms to enhance infection.


  • Open Access

    Crosstalk of HDAC4, PP1, and GSDMD in controlling pyroptosis

    by Weilv Xu, Qiao Jin, Xinyue Li, Danyue Li, Xinyu Fu, Nan Chen, Qian Lv, Yuhua Shi, Suhui He, Lu Dong, et al.

    Gasdermin D (GSDMD) functions as a pivotal executor of pyroptosis, eliciting cytokine secretion following cleavage by inflammatory caspases. However, the role of posttranslational modifications (PTMs) in GSDMD-mediated pyroptosis remains largely unexplored. In this study, we demonstrate that GSDMD can undergo acetylation at the Lysine 248 residue, and this acetylation enhances pyroptosis. We identify histone deacetylase 4 (HDAC4) as the specific deacetylase responsible for mediating GSDMD deacetylation, leading to the inhibition of pyroptosis both in vitro and in vivo. Deacetylation of GSDMD impairs its ubiquitination, resulting in the inhibition of pyroptosis. Intriguingly, phosphorylation of HDAC4 emerges as a critical regulatory mechanism promoting its ability to deacetylate GSDMD and suppress GSDMD-mediated pyroptosis. Additionally, we implicate Protein phosphatase 1 (PP1) catalytic subunits (PP1α and PP1γ) in the dephosphorylation of HDAC4, thereby nullifying its deacetylase activity on GSDMD. This study reveals a complex regulatory network involving HDAC4, PP1, and GSDMD. These findings provide valuable insights into the interplay among acetylation, ubiquitination, and phosphorylation in the regulation of pyroptosis, offering potential targets for further investigation in the field of inflammatory cell death.